Free tool
FAERS Monitor: Cimerli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761165 or its brand name (Cimerli, Ranibizumab-Eqrn). Reports on generic versions are filed under their own applications.
Reports
162
Serious
22
14% of reports
Hospitalization
0
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective62
- underdose54
- product administration error13
- product contamination9
- product storage error8
- visual impairment8
- circumstance or information capable of leading to medication error7
- death7
- product use issue6
- endophthalmitis5
- product dose omission issue5
- vision blurred5
- off label use4
- wrong technique in product usage process4
- burning sensation3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 14 |
| 2024 | 68 |
| 2025 | 22 |
| 2026 | 58 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,997 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product contaminationSignal | 9 | 329.1 | 174.3 | 2,619 |
| endophthalmitisSignal | 5 | 108.3 | 45.7 | 429 |
| underdoseSignal | 54 | 96.1 | 77.3 | 5,002 |
| product administration errorSignal | 13 | 83.6 | 49.6 | 980 |
| circumstance or information capable of leading to medication errorSignal | 7 | 26.9 | 13.0 | 150 |
| product storage errorSignal | 8 | 11.9 | 6.0 | 69 |
| visual impairmentSignal | 8 | 8.4 | 4.3 | 45 |
| drug ineffectiveSignal | 62 | 6.1 | 5.0 | 277 |
| burning sensationSignal | 3 | 5.6 | 1.8 | 7 |
| vision blurredSignal | 5 | 4.7 | 2.0 | 11 |
| product use issueSignal | 6 | 4.1 | 1.9 | 11 |
| wrong technique in product usage process | 4 | 2.6 | 1.0 | 2 |
| product dose omission issue | 5 | 2.2 | 0.9 | 2 |
| death | 7 | 1.1 | 0.5 | 0 |
| off label use | 4 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.